14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$202.61 (2.64%)

Volume: 806.753k

Closed: Sep 27, 2022

Hollow Logo Score: -2.416

Alnylam Pharmaceuticals Stock Forecast

$202.61 (2.64%)

Volume: 806.753k

Closed: Sep 27, 2022

Score Hollow Logo -2.416
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSI min/max Values: [ 25 - 75 ] RSI14 is 46 and the stock is currently not being overbought or oversold
Last Reaction
Be the first to comment on ALNY

Alnylam Pharmaceuticals stock price up 2.64% on Tuesday
(Updated on Sep 27, 2022)


Sell candidate since 2022-09-26 Gain 2.64% PDF

The Alnylam Pharmaceuticals stock price gained 2.64% on the last trading day (Tuesday, 27th Sep 2022), rising from $197.39 to $202.61. During the last trading day the stock fluctuated 2.14% from a day low at $200.65 to a day high of $204.95. The price has been going up and down for this period, and there has been a -1.93% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 92 thousand more shares were traded than the day before. In total, 807 thousand shares were bought and sold for approximately $163.46 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $196.22 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 46.93% during the next 3 months and, with a 90% probability hold a price between $288.31 and $407.67 at the end of this 3-month period.

Signals & Forecast

Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Alnylam Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $205.41 and $214.55. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, August 12, 2022, and so far it has fallen -13.36%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

Alnylam Pharmaceuticals finds support from accumulated volume at $201.26 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $4.30 between high and low, or 2.14%. For the last week, the stock has had daily average volatility of 3.05%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations For The Upcoming Trading Day Of Wednesday 28th

For the upcoming trading day on Wednesday, 28th we expect Alnylam Pharmaceuticals to open at $202.74, and during the day (based on 14 day Average True Range), to move between $194.20 and $211.02, which gives a possible trading interval of +/-$8.41 (+/-4.15%) up or down from last closing price. If Alnylam Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 8.30% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $201.26 (0.67%) than the resistance at $212.00 (4.63%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Alnylam Pharmaceuticals stock A Buy?

The Alnylam Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Alnylam Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -2.416

Sell Candidate Unchanged

Predicted Opening Price for Alnylam Pharmaceuticals of Wednesday, September 28, 2022

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Fair opening price September 28, 2022 Current price
$202.74 $202.61 (Undervalued)

Remember To Visit Our YouTube Channel

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 207.04 2.18 %
205.39 1.37 %
204.38 0.87 %
Current price: 202.61
Support 201.09 -0.75 %
200.08 -1.25 %
198.44 -2.06 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 224.05 10.58 %
212.01 4.64 %
212.00 4.63 %
Current price 202.61
Support 201.26 -0.67%
197.39 -2.58%
152.49 -24.74%

Click to get the best stock tips daily for free!

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 690 stocks, only a few dozen will trigger such a signal!

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f... ALNY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT